InflaRx NV (IFRX)
1.60
+0.07
(+4.58%)
USD |
NASDAQ |
Oct 09, 16:00
1.59
-0.01
(-0.62%)
After-Hours: 20:00
InflaRx Free Cash Flow : -32.78M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -32.78M |
| March 31, 2026 | -44.56M |
| September 30, 2025 | -47.11M |
| June 30, 2025 | -48.63M |
| March 31, 2025 | -55.07M |
| September 30, 2024 | -51.68M |
| June 30, 2024 | -46.20M |
| March 31, 2024 | -45.59M |
| December 31, 2023 | -40.72M |
| September 30, 2023 | -35.20M |
| June 30, 2023 | -31.21M |
| March 31, 2023 | -31.44M |
| December 31, 2022 | -34.58M |
| September 30, 2022 | -41.14M |
| June 30, 2022 | -50.66M |
| March 31, 2022 | -47.56M |
| Date | Value |
|---|---|
| December 31, 2021 | -45.69M |
| September 30, 2021 | -45.49M |
| June 30, 2021 | -45.55M |
| March 31, 2021 | -44.57M |
| December 31, 2020 | -43.63M |
| September 30, 2020 | -49.21M |
| June 30, 2020 | -46.99M |
| March 31, 2020 | -50.18M |
| December 31, 2019 | -48.49M |
| September 30, 2019 | -40.34M |
| June 30, 2019 | -35.88M |
| March 31, 2019 | -30.73M |
| December 31, 2018 | -27.98M |
| September 30, 2018 | -22.83M |
| June 30, 2018 | -22.38M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| MediGene AG | -- |
| BioNTech SE | 424.34M |
| Immatics NV | -246.23M |
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.937M |
| Cash from Investing (Quarterly) | 14.90M |
| Cash from Financing (Quarterly) | 138.70M |
| Free Cash Flow Per Share (Quarterly) | -0.0253 |
| Free Cash Flow to Equity (Quarterly) | -2.984M |
| Free Cash Flow to Firm (Quarterly) | -2.962M |
| Free Cash Flow Yield | -25.18% |